Hopefully, you're right. But what new findings do they have to say? I am stuck on this until ASH meeting in December.
That's where you're wrong son. If you actually look at my previous posts, I have been long on this stock. But seeing the pattern, I know it will drift back down to under 3. Mark this post.
Even if their trial is a success, a Mom and Pop pharmaceutical operations like Jacobus has no capacity whatsoever to manufacture 3,4-Dap to all LEMS population. They should stick to supplying Dapsone to Lepers IMO.
"I also don't expect a new CEO as we may already have suitor(s) lined up and negotiating."
They have to announce a new CEO first even if it's just for formality. Otherwise, we have to wait until Harvey retires in December because that's the deal.